Cutaneous Adverse Events Associated with Immune Checkpoint Inhibitors: A Review Article

Immune checkpoint inhibitors (ICIs) have emerged as novel options that are effective in treating various cancers. They are monoclonal antibodies that target cytotoxic T-lymphocyte antigen 4 (CTLA-4), programmed cell death 1 (PD-1), and programmed cell death-ligand 1 (PD-L1). However, activation of t...

全面介紹

書目詳細資料

發表在:	Current Oncology
Main Authors:	Chieh-Hsun Chen, Hsin-Su Yu, Sebastian Yu
格式:	Article
語言:	英语
出版:	MDPI AG 2022-04-01
主題:	immune checkpoint inhibitor immune-related adverse event cutaneous immune-related adverse event anti-CTLA-4 inhibitor anti-PD-1 inhibitor anti-PD-L1 inhibitor
在線閱讀:	https://www.mdpi.com/1718-7729/29/4/234